Restoring immune tolerance in neuromyelitis optica Part I

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 5, 2016, Pages

  Steinman, Larry ^a   Bar Or, Amit ^b   Behne, Jacinta M ^c   Benitez Ribas, Daniel ^d   Chin, Peter S ^e   Clare Salzler, Michael ^f   Healey, Donald ^g   Kim, James I ^h   Kranz, David M ⁱ   Lutterotti, Andreas ^j   Martin, Roland ^j   Schippling, Sven ^j   Villoslada, Pablo ^d   Wei, Cheng Hong ^k   Weiner, Howard L ^k,l   Zamvil, Scott S ^h,m   Yeaman, Michael R ⁿ   Smith, Terry J ^o  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Guthy Jackson Charitable Foundation   (United States)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e GENENTECH INC   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g Opexa Therapeutics Inc   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k Forest Landing Court ^*

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ HARBOR UCLA MEDICAL CENTER   (United States)

^o UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016998717     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000276     Document Type: Review

References (58)

1. Levy M, Wildemann B, Jarius S, et al. Immunopathogenesis of neuromyelitis optica. Adv Immunol 2014;121:213–242.
2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–189.
3. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202:473–477.
4. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability, and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicenter retrospective observational study from the UK. Mult Scler 2014;20:1533–1540.
5. Nakamura M, Nakazawa T, Doi H, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol 2010; 248:1777–1785.
6. Miller SD, Wetzig RP, Claman HN. The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med 1979;149:758–773.
7. Oh S, Schwartz RH, Singh NJ. Development and tolerization of hyperacute rejection in a transgenic mouse graft versus host model. Transplantation 2012;94:234–240.
8. Castells M. Rapid desensitization of hypersensitivity reactions to chemotherapy agents. Curr Drug Saf 2006;1:243–251.
9. Fousteri G, Bresson D, von Herrath M. Rational development of antigen-specific therapies for type 1 diabetes. Adv Exp Med Biol 2007;601:313–319.
10. Turley DM, Miller SD. Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis. Results Probl Cell Differ 2010;51:217–235.
11. Mori K, Yamanishi H, Ikeda Y, et al. Oral administration of carbonic anhydrase I ameliorates murine experimental colitis induced by Foxp3-CD41CD252 T cells. J Leukoc Biol 2013;93:963–972.
12. Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996;274:2054–2057.
13. Dolgin E. The inverse of immunity. Nat Med 2010;16: 740–743.
14. Steinman L. Inverse vaccination, the opposite of Jenner’s concept, for therapy of autoimmunity. J Intern Med 2010; 267:441–451.
15. Hinson SR, McKeon A, Lennon VA. Neurological autoimmunity targeting aquaporin-4. Neuroscience 2010;168: 1009–1018.
16. Sato DK, Callegaro D, de Haidar Jorge FM, et al. Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks. Ann Neurol 2014;76:305–309.
17. Steinman L. The re-emergence of antigen-specific tolerance as a potential therapy for MS. Mult Scler 2015;21: 1223–1238.
18. Roep BO, Solvason N, Gottlieb PA, et al. Plasmid encoded proinsulin preserves C-peptide while specifically reducing proinsulin specific CD8 T cells in type 1 diabetes. Sci Transl Med 2013;5:191ra82.
19. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005;435: 612–619.
20. Garren H, Robinson WH, Krasulová E, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008;63:611–620.
21. Bar-Or A, Vollmer T, Antel J, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007;64: 1407–1415.
22. Selmi C. Autoimmunity in 2012. Clin Rev Allergy Immunol 2013;45:290–301.
23. Martin A, Tisch RM, Getts DR. Manipulating T cell-mediated pathology: targets and functions of monoclonal antibody immunotherapy. Clin Immunol 2013;148: 136–147.
24. Salvana EM, Salata RA. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009;22:274–290.
25. Madakamutil LT, Maricic I, Sercarz EE, Kumar V. Immunodominance in the TCR repertoire of a TCR peptide-specific CD41 Treg population that controls experimental autoimmune encephalomyelitis. J Immunol 2008;180:4577–4585.
26. Buckner JH. Mechanisms of impaired regulation by CD4 (1)CD25(1)FOXP3(1) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849–859.
27. Linhares UC, Schiavoni PB, Barros PO, et al. The ex vivo production of IL-6 and IL-21 by CD41 T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 2013;33:179–189.
28. Pohl M, Fisher MT, Mader S, et al. Pathogenic T cells responses against aquaporin 4. Acta Neuropathol 2011; 122:21–34.
29. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize clostridium ABC transporter. Ann Neurol 2012;72:53–64.
30. Kumar V, Sercarz EE. The involvement of T cell receptor peptide-specific regulatory CD41 T cells in recovery from antigen-induced autoimmune disease. J Exp Med 1993; 178:909–916.
31. Zhang J. T cell vaccination as an immunotherapy for autoimmune diseases. Cell Mol Immunol 2004;1:321–327.
32. Huang X, Wu H, Lu Q. The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol 2014;47: 219–233.
33. Fontana R, Bregni M, Cipponi A, et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood 2009;113:1651–1660.
34. Fox E, Wynn D, Cohan S, Rill D, McGuire D, Markowitz C. A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Mult Scler 2012; 18:843–852.
35. Chen G, Li N, Zang YC, et al. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum 2007;56:453–463.
36. Li ZG, Mu R, Dai ZP, Gao XM. T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus 2005;14:884–889.
37. Leavy O. Dendritic cells: tracing the origins of cDCs. Nat Rev Immunol 2013;13:703.
38. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296–306.
39. Vacchelli E, Vitale I, Eggermont A, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012;1:1111–1134.
40. Mantia-Smaldone GM, Chu CS. A review of dendritic cell therapy for cancer: progress and challenges. BioDrugs 2013;27:453–468.
41. Segovia-Gamboa N, Rodriguez-Arellano ME, Rangel-Cruz R, et al. Tolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin- and glutamic acid decarboxylase 65-autoreactive T lymphocytes from type 1 diabetic patients. Clin Immunol 2014;154:72–83.
42. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011;34:2026–2032.
43. Boks MA, Kager-Groenland J, Haasjes MSP, Zwaginga JJ, van Ham SM, ten Brinke A. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction- a comparative study on human clinical-applicable DC. Clin Immunol 2012;142:332–342.
44. Saito M, Nagasaw M, Takada H, et al. Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. J Exp Med 2011;208:235–249.
45. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 2007;7:665–677.
46. Karpus WJ, Pope JG, Peterson JD, Dal Canto MC, Miller SD. Inhibition of Theiler’s virus-mediated demyelination by peripheral immune tolerance induction. J Immunol 1995;155:947–957.
47. Kennedy KJ, Smith WS, Miller SD, Karpus WJ. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis: a comparison between oral and peripheral tolerance. J Immunol 1997;159:1036–1044.
48. Kennedy MK, Tan LJ, Dal Canto MC, et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol 1990;144:909–915.
49. Turley DM, Miller SD. Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol 2007;178:2212–2220.
50. Getts DR, Turley DM, Smith CE, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L11 and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol 2011;187:2405–2417.
51. Luo X, Pothoven KL, McCarthy D, et al. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci USA 2008;105:14527–14532.
52. Lutterotti A, Yousef S, Sputtek A, et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med 2013;5:188ra75.
53. Bielekova B, Sung MH, Kadom N, Simon R, McFarland HF, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD41 T cells in multiple sclerosis. J Immunol 2004;172:3893–3904.
54. Jenkins MK, Mueller D, Schwartz RH, et al. Induction and maintenance of anergy in mature T cells. Adv Exp Med Biol 1991;292:167–176.
55. Peschl P, Reindl M, Schanda K, Sospedra M, Martin R, Lutterotti A. Anti-myelin antibody responses following induction of antigen-specific tolerance with antigen-coupled cells. J Neuroimmunol 2014;275:12.
56. Tuohy VK, Yu M, Yin L, Kawczak JA, Kinkel PR. Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun 1999;13:11–20.
57. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85–95.
58. Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev 2014;257:145–164.